 |
Keyword Search |
|
|
|
| |
|
|
|
 | Event ID : ADDF_SD
Alzheimers Drug Discovery Foundation
5th DRUG DISCOVERY FOR NEURODEGENERATION: An Intensive Course on Translating Research into Drugs
San Diego, CA
February 6-8, 2011
ABOUT THE MEETING The purpose of the Drug Discovery for Neurodegeneration course is to advance drug discovery for neurodegenerative diseases by educating scientists on the process of translating basic research into novel therapies.
The course is designed to give participants knowledge and relevant resources about this field of scientific investigation and address the associated barriers and challenges. The program will focus on Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis.
| COURSE OBJECTIVES |
-
Train a cadre of interdisciplinary scientists in the principles of drug discovery for neurodegenerative disease;
-
Provide a platform to exchange ideas, knowledge and resources about drug discovery for neurodegenerative disease;
-
Stimulate pre-clinical research in the discovery and testing of novel compounds aimed at the prevention and treatment of neurodegenerative disease; and
-
Build public-private partnerships that will accelerate drug discovery for neurodegenerative disease. |
TARGET AUDIENCE
-
Academic and industry scientists engaged in drug discovery research for neurodegenerative disease or CNS
-
Business development and licensing professionals
-
Alliance management professionals
-
Venture capitalists and other investors
For more information visit: http://www.worldeventsforum.com/addf/drugdiscovery/ |
| | PLENARY: The Neurovascular Unit: Biology of Blood Brain Barrier in Neurodegenerative Diseases | | | |
Objectives :
The purpose of the conference is to advance drug discovery for neurodegenerative diseases by educating scientists on the process of translating basic research into novel therapies.
Speakers and chairs present lectures and case studies on Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, ALS, MS, and other orphan neurological diseases.
|
______________________
Overview of Drug Discovery for Neurodegenerative Diseases
Speaker(s) : Howard Fillit MD
______________________
The Neurovascular Unit: Biology of Blood Brain Barrier in Neurodegenerative Diseases
Speaker(s) : Berislav Zlokovic MD, PhD
| | I. Basics of Medicinal Chemistry | | | |
Objectives :
The goal of this session is to review fundamentals of medicinal chemistry relevant to drug discovery for CNS disorders. Although the focus is on small molecule drugs, due to the extensive state of knowledge, general themes relevant to peptide and protein therapeutics will also be discussed. The attendee should leave the session with a practical, working familiarity of contemporary approaches and key issues that should be considered by interdisciplinary teams as they take hits to lead compounds to candidate small molecule therapeutics.
|
______________________
Overview: Medicinal Chemistry Rules of Thumb, Myths and Realities in CNS Drug Discovery
Speaker(s) : D. Martin Watterson, PhD
______________________
Designing Small Molecules with Increased Potential for CNS Penetration
Speaker(s) : Laura Chico, PhD
______________________
Synthetic Chemistry Essentials for Biologists
Speaker(s) : Heather Behanna, PhD
______________________
Structure Assisted Ligand Design
Speaker(s) : Vicki Nienaber, PhD
| | II. Early Phases of Drug Discovery | | |
______________________
Basics of High Throughput Screening (HTS)
Speaker(s) : James Inglese, PhD
______________________
After HTS: Solubility, Selectivity, Safety and Stability in Addition to Potency
Speaker(s) : Kurt Brunden, PhD
______________________
Importance of Toxicology
Speaker(s) : John E. Sagartz, DVM, PhD
| | III. Pre-Clinical Proof-of-Concept and Development | | |
______________________
What Makes a Clinical Candidate?
Speaker(s) : William Potter, MD, PhD
______________________
Requirements for an IND
Speaker(s) : Edward Spack, PhD
______________________
The Limitations and Value of Animal Models for Neurodegenerative Disease
Speaker(s) : Steve Perrin, PhD
______________________
Regulatory Requirements in Preparing for Clinical Trials
Speaker(s) : Eric Bastings, MD
| | IV. Issues in Technology Transfer: Interactions and Intellectual Property | | |
______________________
Working Effectively with Your TTO: Technology Evaluation Process and IP Protection
Speaker(s) : Kathleen Denis, PhD
______________________
Creating Mutually Beneficial Relationships with Industry: Needs, Wants and Paperwork
Speaker(s) : Louis Berneman, EdD
______________________
Should You Start a Biotechnology Company?
Speaker(s) : John S. Swartley, PhD
| | V. Beyond Small Molecules: Natural Products, Biologics and Repurposing | | |
______________________
Natural Products as Drug Starting Points
Speaker(s) : Frank Koehn, PhD
______________________
Unique Challenges for Biologics
Speaker(s) : Joao Siffert, PhD
______________________
The Road to Repurposing a Drug: Isradipine
Speaker(s) : D. James Surmeier, PhD
______________________
Neurotrophic Factor Mimetics: Target Validation to Lead Optimization
Speaker(s) : Frank Longo, MD, PhD
______________________
Development of Tysabri for Multiple Sclerosis
Speaker(s) : Ted Yednock, MD
______________________
Novel Ways to Reduce Protein Aggregation
Speaker(s) : Alan Snow, PhD
| | VII. Resources and Services For Advancing Drug Discovery | | |
______________________
Academic Models of Drug Discovery Services & Utilizing CROs
Speaker(s) : Marcie Glicksman, PhD
______________________
Resources at the National Institute of Health
Speaker(s) : Neil Buckholtz, PhD , Rebecca Farkas, PhD
|
|
